SCHEMBL2919149

SCHEMBL2919149

CN(C)CCNC(=O)c1n[nH]c2cc(N)ccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WNT1 P04628 3/20 0.58
DYRK1A Q13627 3/20 0.58
SMN1; SMN2 Q16637 3/20 0.51
KDM4E B2RXH2 1/20 0.51
ITGB3 P05106 1/20 0.47
ITGA2B P08514 1/20 0.47
ABL1 P00519 2/20 0.46
BCR P11274 2/20 0.46
RAB9A P51151 3/20 0.45
NPC1 O15118 2/20 0.45
ALDH1A1 P00352 1/20 0.45
MAPK8 P45983 2/20 0.45
MAPK10 P53779 2/20 0.45
MAPK14 Q16539 2/20 0.45
HTR2C P28335 1/20 0.43
MAPK1 P28482 1/20 0.42
MEN1 O00255 1/20 0.42
GAA P10253 1/20 0.42
KMT2A Q03164 1/20 0.42
SIRT1 Q96EB6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2918904 0.81 WNT1 (0.52) WNT1DYRK1ASMN1; SMN2KDM4EITGB3
SCHEMBL14574204 0.77 HTT (0.47) SMN1; SMN2KDM4EITGB3ITGA2BALDH1A1
SCHEMBL27201405 0.74 DYRK1A (0.67) WNT1DYRK1AABL1BCRGSK3B
SCHEMBL27201435 0.74 DYRK1A (0.64) WNT1DYRK1AGSK3B
SCHEMBL17095563 0.74 DYRK1A (1.00) WNT1DYRK1AGSK3B
SCHEMBL14574212 0.73 KDM4E (0.63) SMN1; SMN2KDM4ERAB9ANPC1ALDH1A1
SCHEMBL17095647 0.73 DYRK1A (1.00) WNT1DYRK1AGSK3B
SCHEMBL2919160 0.72 PRKAG1 (0.48)
SCHEMBL2011282 0.72 WNT1 (0.52) WNT1DYRK1ASMN1; SMN2KDM4ERAB9A
SCHEMBL2911439 0.72 WNT1 (0.49) WNT1DYRK1ASMN1; SMN2KDM4EMAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE DSTYK, ABL1, EEF2K WNT1 4594/4885DYRK1A 523/4885SMN1; SMN2 4744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.